Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandra Lespagnol

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Clinical Genitourinary Cancer|July 23, 2016
Synchronous Metastatic Clear-Cell Renal Cell Carcinoma: A Distinct Morphologic, Immunohistochemical, and Molecular PhenotypeSolene-Florence Kammerer-Jacquet, Angelique Brunot, Adelaide Pladys, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 13, 2014
Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordancesFlorian Cabillic, Audrey Gros, Frédéric Dugay, et al.
Clinical Genitourinary Cancer|March 7, 2019
Metastatic Clear-cell Renal Cell Carcinoma With a Long-term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 ExpressionSolène-Florence Kammerer-Jacquet, Angelique Brunot, Mathilde Lefort, et al.
Urologic Oncology|June 17, 2017
Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatmentSolène-Florence Kammerer-Jacquet, Angelique Brunot, Karim Bensalah, et al.
International Journal of Clinical Oncology|March 28, 2020
Implementation of a molecular tumor board at a regional level to improve access to targeted therapyHéloïse Bourien, Alexandra Lespagnol, Boris Campillo-Gimenez, et al.
Targeted Oncology|May 28, 2017
Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line TherapySolène-Florence Kammerer-Jacquet, Sarah Medane, Karim Bensalah, et al.
European Journal of Cancer (Oxford, England : 1990)|October 26, 2021
Standardisation of pathogenicity classification for somatic alterations in solid tumours and haematologic malignanciesFlorence Koeppel, Etienne Muller, Alexandre Harlé, et al.
International Journal of Cancer|September 14, 2016
Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potentialSolène-Florence Kammerer-Jacquet, Laurence Crouzet, Angélique Brunot, et al.
EMBO Reports|March 29, 2024
TCTP regulates genotoxic stress and tumorigenicity via intercellular vesicular signalingRobert Amson, Andrea Senff-Ribeiro, Teele Karafin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2021
Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 BlockadeStéphane Terry, Cécile Dalban, Nathalie Rioux-Leclercq, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Clinical Genitourinary Cancer|July 23, 2016
Synchronous Metastatic Clear-Cell Renal Cell Carcinoma: A Distinct Morphologic, Immunohistochemical, and Molecular PhenotypeSolene-Florence Kammerer-Jacquet, Angelique Brunot, Adelaide Pladys, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 13, 2014
Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordancesFlorian Cabillic, Audrey Gros, Frédéric Dugay, et al.
Clinical Genitourinary Cancer|March 7, 2019
Metastatic Clear-cell Renal Cell Carcinoma With a Long-term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 ExpressionSolène-Florence Kammerer-Jacquet, Angelique Brunot, Mathilde Lefort, et al.
Urologic Oncology|June 17, 2017
Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatmentSolène-Florence Kammerer-Jacquet, Angelique Brunot, Karim Bensalah, et al.
International Journal of Clinical Oncology|March 28, 2020
Implementation of a molecular tumor board at a regional level to improve access to targeted therapyHéloïse Bourien, Alexandra Lespagnol, Boris Campillo-Gimenez, et al.
Targeted Oncology|May 28, 2017
Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line TherapySolène-Florence Kammerer-Jacquet, Sarah Medane, Karim Bensalah, et al.
European Journal of Cancer (Oxford, England : 1990)|October 26, 2021
Standardisation of pathogenicity classification for somatic alterations in solid tumours and haematologic malignanciesFlorence Koeppel, Etienne Muller, Alexandre Harlé, et al.
International Journal of Cancer|September 14, 2016
Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potentialSolène-Florence Kammerer-Jacquet, Laurence Crouzet, Angélique Brunot, et al.
EMBO Reports|March 29, 2024
TCTP regulates genotoxic stress and tumorigenicity via intercellular vesicular signalingRobert Amson, Andrea Senff-Ribeiro, Teele Karafin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2021
Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 BlockadeStéphane Terry, Cécile Dalban, Nathalie Rioux-Leclercq, et al.
Pageof 4